Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

<p>Raw RNAseq data corresponding to Figures 2C, 4D and Supplemental Figure 2B</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Christopher T. Letson (16424095) (author)
Бусад зохиолчид:	Maria E. Balasis (15033630) (author), Hannah Newman (15033618) (author), Moritz Binder (16424098) (author), Alexis Vedder (16424101) (author), Fumi Kinose (16424104) (author), Markus Ball (15033633) (author), Traci Kruer (15134201) (author), Ariel Quintana (16424107) (author), Terra L. Lasho (16424110) (author), Christy M. Finke (16424113) (author), Luciana L. Almada (16424116) (author), Jennifer M. Grants (16424119) (author), Guolin Zhang (15098544) (author), Martin E. Fernandez-Zapico (16424122) (author), Alexandre Gaspar-Maia (16424125) (author), Jeffrey Lancet (16424128) (author), Rami Komrokji (16424131) (author), Eric Haura (16424134) (author), David A. Sallman (15134216) (author), Gary W. Reuther (16424137) (author), Aly Karsan (15024852) (author), Uwe Rix (15040221) (author), Mrinal M. Patnaik (16424140) (author), Eric Padron (15134222) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Growth factors Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Translational Research
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
-н: Christopher T. Letson (16424095)
Хэвлэсэн: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
-н: Christopher T. Letson (16424095)
Хэвлэсэн: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
-н: Christopher T. Letson (16424095)
Хэвлэсэн: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
-н: Christopher T. Letson (16424095)
Хэвлэсэн: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
-н: Yun-Guang Hong (14960966)
Хэвлэсэн: (2025)

Supplementary Tables S1-S4 from A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
-н: Fengbiao Zhou (15123670)
Хэвлэсэн: (2025)

Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
-н: Yiming Wu (15306005)
Хэвлэсэн: (2025)

Supplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
-н: Chao Shen (22548301)
Хэвлэсэн: (2025)

Supplementary Tables from Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
-н: Elizabeth A. Raupach (21718352)
Хэвлэсэн: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
-н: Ana Vujovic (15207479)
Хэвлэсэн: (2025)

Figure S1 from ANGEL2 Modulates Wild-type TP53 Translation and Doxorubicin Chemosensitivity in Colon Cancer
-н: Christopher August Lucchesi (21643673)
Хэвлэсэн: (2025)

Figure S2 from ANGEL2 Modulates Wild-type TP53 Translation and Doxorubicin Chemosensitivity in Colon Cancer
-н: Christopher August Lucchesi (21643673)
Хэвлэсэн: (2025)

Figure S3 from ANGEL2 Modulates Wild-type TP53 Translation and Doxorubicin Chemosensitivity in Colon Cancer
-н: Christopher August Lucchesi (21643673)
Хэвлэсэн: (2025)

Figure S4 from ANGEL2 Modulates Wild-type TP53 Translation and Doxorubicin Chemosensitivity in Colon Cancer
-н: Christopher August Lucchesi (21643673)
Хэвлэсэн: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
-н: Jonathan M.J. Derry (16648337)
Хэвлэсэн: (2025)

Table S1 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
-н: Xun-Xi Lu (14952883)
Хэвлэсэн: (2025)

Table S2 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
-н: Xun-Xi Lu (14952883)
Хэвлэсэн: (2025)

Table S3 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
-н: Xun-Xi Lu (14952883)
Хэвлэсэн: (2025)

Table S7 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
-н: Xun-Xi Lu (14952883)
Хэвлэсэн: (2025)

Table S8 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
-н: Xun-Xi Lu (14952883)
Хэвлэсэн: (2025)

Supplementary Figure 1 from The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer
-н: Shayna Thomas-Jardin (21718061)
Хэвлэсэн: (2025)